‘Scoop Up,’ Says Morgan Stanley on UnitedHealth Stock (UNH) Ahead of Earnings

UnitedHealth heads into Q1 earnings with sentiment improving after CMS finalized a 2027 Medicare Advantage rate increase of 2.48%, versus just 0.09% in the original proposal and about +240bps better than the advance notice. Morgan Stanley moved UNH to Top Pick, citing clearer margin visibility, progress in Medicare Advantage and Optum Health turnaround, and potential AI-driven efficiencies. The analyst expects Q1 MLR of 85.3% versus 85.5% consensus and set a $375 price target, implying 15.5% upside.

Analysis

The setup is less about a single quarter and more about whether UNH can finally shift from “show me” to “prove me” mode. The favorable rate reset matters because it reduces the probability of another downward earnings-reset cycle, which is the main overhang on managed care multiples; if investors believe 2027 margin pressure is now bounded, the stock can re-rate well before the actual earnings benefit shows up.

The more interesting second-order effect is relative positioning versus other managed care names: UNH has the scale and operating leverage to translate even modest MA margin stabilization into outsized EPS revision momentum, while smaller peers are more exposed to local benefit design and utilization noise. That means a clean print could trigger not just absolute upside in UNH, but also a rotation of capital within the group toward the highest-quality compounder and away from weaker operators whose margin recovery depends on more fragile assumptions.

The main risk is that investors are conflating lower long-dated regulatory risk with near-term operational improvement. If Q1 shows any evidence that utilization is still running hot, or that Optum’s turnaround remains more narrative than numbers, the market will likely fade the good-news story and re-focus on 2025 execution. In other words, the stock needs a sequence of clean quarters, not just a better headline, to sustain a rerating.

Contrarian angle: the consensus may be underestimating how much of the rerating is already embedded in expectations after the policy relief. That suggests the cleaner expression may be relative value rather than outright beta — own UNH against the weaker managed care laggards, or use options to capture a post-earnings pop without underwriting a full de-rating if management disappoints on the operating bridge.

Key Decisions for Investors

• Go long UNH into the print only via upside structures: buy 1-2 month call spreads or a small cash equity position sized for a 5-7% post-earnings move; reward is a momentum rerate toward prior highs, but stop if management sounds defensive on utilization or Optum execution.
• Pair trade: long UNH / short a lower-quality managed care peer basket over the next 1-3 months to express relative outperformance from rate clarity and scale advantages; this is cleaner than a naked long if the sector trades choppy on headline risk.
• If Q1 is merely in line and the stock opens weak, buy the dip only if the selloff is >3-4% and volume is exhaustion-like; the setup favors mean reversion because the key catalyst is reduced future downside, not just this quarter's EPS.
• Use the earnings call to assess whether operating commentary confirms 2027-2028 margin uplift; if management does not validate the multi-quarter improvement path, fade rallies and expect the stock to revert to a low-multiple range.